Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.

Company Announcement
03 October 2023

Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Kashiv Biosciences LLC (“Kashiv”), a fully...
Company Announcement
25 September 2023

Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in...
Company Announcement
20 September 2023

Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food...
Company Announcement
11 September 2023

Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st...
Company Announcement
05 September 2023

Alvotech Announces Changes to the Leadership Team

Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has...
Financial Reports
30 August 2023

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s...
Company Announcement
29 August 2023

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned...
Company Announcement
22 August 2023

Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Managers’ Transactions
18 August 2023

Transactions of Managers and Closely Associated Persons

Company Announcement
31 July 2023

Alvotech Completes $100 Million Convertible Bond Private Placement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement,...
1…1819…32